Slide 1: Welcome to 2026 Analyst Day
Welcome to 2026 Analyst Day Matt Bacso VP, Investor Relations © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and accompanying oral presentation contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected financial results of PROCEPT BioRobotics Corporation (the “Company”). Words such as “anti
Slide 3: Use of Non-GAAP Financial Information
Use of Non-GAAP Financial Information In addition to financial information presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation and the accompanying oral statements include certain non-GAAP financial measures, which include non-GAAP Adjusted EBITDA.
Slide 4: The Next Chapter for PROCEPT
The Next Chapter for PROCEPT Larry L Wood Chief Executive Officer © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 4
Slide 5: A Large, Underpenetrated BPH Market with a Disciplined Path to Growth
A Large, Underpenetrated BPH Market with a Disciplined Path to Growth • BPH is significantly undertreated ~40 MILLION U.S. men living with BPH • Many patients fear the procedure more than 8M treated or previously treated with medication their condition actively on discontinued 6.7M medication 1.1M d
Slide 6: PROCEPT Biorobotics Stands on a Strong Foundation
PROCEPT Biorobotics Stands on a Strong Foundation The Next Chapter Accelerate Game-changing Procedure Growth Technology Drive Path to Profitability Deep Clinical Evidence Base Advance Evidence and Innovation We are now moving from establishing Aquablation® as a therapy to leading BPH treatment Data
Slide 7: Growing Procedures and Install Base Paired With Strong Reimbursement
Growing Procedures and Install Base Paired With Strong Reimbursement Worldwide Aquablation Procedures 60000 >125K patients treated worldwide >900 50000 global 40000 install base 30000 20000 10000 Category I Reimbursement 0 as of January 1, 2026 2023 2024 2025 Aquablation is ready to move to the stan
Slide 8: Benefits of Improved Organizational Discipline
DRIVE PATH TO Benefits of Improved Organizational Discipline PROFITABILITY % HP to Procedure HP Pricing ($000) +9% YOY 120% 115% $3.50 100% $3.34 $3.15 $3.19 77% 2022 - 2024 1Q25 - 3Q25 4Q25 2026 2022 - 2024 1Q25 - 3Q25 4Q25 2026 Two positive structural effects: Higher-than-expected ASP and improved
Slide 9: Realignment of the Commercial Organization
ACCELERATE Realignment of the Commercial Organization PROCEDURE GROWTH HISTORICAL MODEL REALIGNMENT Clinical Procedure Procedure Team Support Area Vice Presidents Sales Support Regional Directors Capital Clinical Sales Distinct management structures, Procedure Support Support independent goals and i
Slide 10: We Have Formed Dedicated Launch Teams
We Have Formed Dedicated Launch Teams HISTORICAL MODEL NEW LAUNCH TEAM MODEL Capital Procedure Capital Procedure Team Team Team Team Grow existing Launch New Grow existing procedures Accounts procedures Launch New • Capital Rep Accounts • Strong clinical support • Strong sales support • Reimbursemen
Slide 11: We Have Formed Dedicated Launch Teams
We Have Formed Dedicated Launch Teams NEW LAUNCH TEAM MODEL In pilot accounts in Q42025, we saw a ~50% reduction in Capital Procedure time from PO to first Team Team ten cases Launch New Grow existing Accounts procedures The net result is a dedicated launch team of experts who standardize the pathwa
Slide 12: Greenfield Placements Remain Core to Capital Revenue
ACCELERATE Greenfield Placements Remain Core to Capital Revenue PROCEDURE GROWTH Greenfield Placements Targeted Exploring Replacement Remain Primary Driver Strategy Leasing Pilots ~70% of Greenfield unit ASP Alternative capital acquisition strategies enable us to expand access to additional customer
Slide 13: Making the Clinical Case for Aquablation
Making the Clinical Case for Aquablation © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 13
Slide 14: Supported by a Robust Body of Evidence
ACCELERATE Supported by a Robust Body of Evidence PROCEDURE GROWTH WATER WATER II WATER III REAL-WORLD EVIDENCE OPEN WATER REAL-WORLD EVIDENCE Data from thousands of patients published with ~250 PubMed citations 14
Slide 15: Aquablation is Growing Within the BPH Category
ACCELERATE Aquablation is Growing Within the BPH Category PROCEDURE GROWTH All BPH Volume Trends (Excluding TURP) 100,000 Rezum Urolift Aquablation 50,000 Enucleation Greenlight Simple Prostatectomy - 2020 2021 2022 2023 2024 2025 2026 E* Aquablation trending towards becoming the leading modern surg
Slide 16: Aquablation is Closing the Gap with TURP
ACCELERATE Aquablation is Closing the Gap with TURP PROCEDURE GROWTH Resective BPH Volume Trends 250,000 Aquablation 200,000 Enucleation Greenlight 100,000 Simple Prostatectomy TURP - 2020 2021 2022 2023 2024 2025 2026 E* Aquablation is now the leading resective BPH treatment – second only to TURP D
Slide 17: Aquablation Delivers a Complete Solution Across All Prostate Sizes
ACCELERATE Aquablation Delivers a Complete Solution Across PROCEDURE GROWTH All Prostate Sizes PRIORITIZE TURP & PVP PRIORITIZE Sexual Function Symptom and Continence Relief Preservation MIST Enucleation & Simple Sexual Function and Continence Symptom Preservation Relief A COMPLETE SOLUTION FOR BPH
Slide 18: Physicians Often Take a Stepwise Approach to Treatment
ACCELERATE Physicians Often Take a Stepwise Approach to Treatment PROCEDURE GROWTH Resective procedure Non-resective procedures Medical Management Physicians Start with the Least Invasive Option, Then the Next Least Invasive Option Market research data on file 18
Slide 19: Most Important Factors Impacting Which Surgery to Choose
ACCELERATE PROCEDURE GROWTH Most Important Factors Impacting Which Surgery to Choose Risk of bladder control issues after surgery 68% Minimizing the likelihood of needing another procedure/surgery 64% Magnitude of symptom relief 58% Recovery time and ease 51% Risk of erectile dysfunction 49% Risk of
Slide 20: These procedures involve a 24F catheter in the urethra
ACCELERATE PROCEDURE GROWTH These procedures involve a 24F catheter in the urethra – no one wants that more than once Patients deserve to have a procedure that offers a complete solution with the best opportunity to avoid a second intervention 20
Slide 21: Patients Want One Procedure Only
Patients Want One Procedure Only 100% Simple Prostatectomy Aquablation HoLEP Re-operation-free rate (%) 95% REFERENCE TURP STANDARD 90% Rezūm PVP UroLift 85% 80% PAE 75% 0 1 2 3 4 5 6 7 8 9 10 Time after index procedure (years) Rubin B, et al. National review of re-operation rates for modern benign
Slide 22: Our Innovation Portfolio
Our Innovation Portfolio © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 22
Slide 23: HYDROS System: Next Generation Robotic Platform
ADVANCE EVIDENCE HYDROS® System: Next Generation Robotic Platform AND INNOVATION HYDROS: The First AI-Enabled Robotic Platform for BPH • AI-Interpreted Live Ultrasound Guidance: Personalized treatment planning combined with surgeon judgment • Robotic Resection: Precise, reproducible tissue removal w
Slide 24: Continued pipeline investment
ADVANCE EVIDENCE AND INNOVATION We expect Global expansion Continued HYDROS to of HYDROS represent the pipeline underway – majority of the UK launch has begun investment install base by the end of 2026 International represents an untapped opportunity and a more meaningful growth contributor over tim
Slide 25: The Next Frontier: Prostate Cancer
ADVANCE EVIDENCE The Next Frontier: Prostate Cancer AND INNOVATION Aquablation PCa Prostate Cancer A Strategic Adjacency • Technology • Installed Base • Commercial Infrastructure 25
Slide 26: This is an Area That is Very Familiar To Me
This is an Area That is Very Familiar To Me Transcatheter Open Heart Surgery (AVR) Valve Replacement (TAVR) Watchful waiting was common until the suffering became unbearable 26
Slide 27: The fastest growing treatment for prostate cancer: Active Surveillance
ADVANCE EVIDENCE AND INNOVATION The fastest growing treatment ACTIVE SURVEILLANCE! for prostate cancer : Radical Prostatectomy Majority of men experience severe erectile dysfunction 25-33% rate of Urinary Incontinence at 1 year >60% of patients ultimately get treated with a radical prostatectomy or
Slide 28: We believe Aquablation will play a meaningful role in prostate cancer
We believe Aquablation will play a meaningful role in the treatment of prostate cancer 28
Slide 29: Prostate Cancer Opportunity
Multiple Initiatives to Drive Differentiated Growth Across the Horizon Drive Procedure Educate Patients Expand Growth Through That Waiting Applications Improved Execution Isn't Winning ~40 MILLION ~40 MILLION U.S. men living with BPH U.S. men living with BPH 8M treated or previously treated with med
Slide 30: Unlocking Growth: A Closer Look
Unlocking Growth: A Closer Look Pooja Sharma Rao Chief Marketing and Strategy Officer © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 30
Slide 31: Driving an Acceleration in Procedure Growth
Driving an Acceleration in Procedure Growth The Next Chapter: The Pathway to Growth • Sales force realignment Accelerate Accelerate Procedure Growth Procedure Growth • Dedicated launch teams • Share capture through strong clinical differentiation Drive Path to • Targeted patient education and Profit
Slide 32: We Believe This is an Important Inflection Point
We Believe This is an Important Inflection Point >125K WATER patients WATER II treated worldwide WATER III >900 REAL-WORLD EVIDENCE global OPEN WATER install base REAL-WORLD EVIDENCE Category I Reimbursement Maturing body of evidence Data on File at PROCEPT BioRobotics 32
Slide 33: Our Approach Starts Intentionally with Building Belief in Aquablation
Our Approach Starts Intentionally with Building Belief in Aquablation with Clinicians and Practices This sequencing reflects lessons learned Establish the therapy Become the Procedure of Choice Targeted patient education as an accelerant Patients need to encounter physicians and care teams who belie
Slide 34: Our Immediate Focus: Improve Penetration of Aquablation into the Surgical Segment
Our Immediate Focus: Improve Penetration of Aquablation into the Surgical Segment Grounded in what ~40 MILLION patients want, U.S. men living with BPH Aquablation delivers a COMPLETE BPH 8M treated or previously treated with medication solution, supported by a actively on discontinued 6.7M medicatio
Slide 35: Aquablation is a Complete Solution for BPH patients
PATIENTS WANT: 1 Complete Symptom Relief PATIENTS WANT: 2 Preserved Sexual and Urinary Function PATIENTS WANT: 3 One Procedure Only Aquablation is a COMPLETE Solution for BPH patients Market research data on file 35
Slide 36: Symptom Reduction: International Prostate Symptom Score Results
Symptom Reduction: International Prostate Symptom Score Results 35 Severe (20-35) 30 25 20 Moderate 15 (8-19) 10 5 (0-7) Mild 0 Baseline 1-6 Month 1 Year 2 Year 3 Year 4 Year 5 Year India WATER WATER II OPEN WATER FRANCAIS WATER Large Prostates, Helfand Jacksonville Lebanon Hong Kong Stanford Montre
Slide 37: Post Void Residual Results
Post Void Residual Results • PVR: Urine left in the bladder after voiding 450 • BPH: Chronic obstruction forces bladder to work harder and over time impairs bladder function 400 • Why PVR matters: Lower PVR = better emptying, 350 reduced risk of infection 300 • Aquablation removes the obstruction 25
Slide 38: Meta-analysis of functional outcomes following Aquablation
Elterman D, Gilling P, Boehrborn C et al, Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies. BMJ Surg Interv Health 38 Technologies 2021.
Slide 39: IPSS Question Results After Aquablation
Mean, 95% Cl Mean, 95% Cl Mean, 95% CI IPSS Q1: Incomplete Emptying IPSS Q2: Frequency | | I IPSS Q3: Intermittency Months after Aquablation IPSS Q7: Nocturia lhe ‘Months ater Aquablation 3 Months after Aquablation 4 i 1B Vedian lobe No 1 . I A Pesos vrs itt 5° Ss ry fy B> 8 € < 8 8 Fnac” lwew: er 6
Slide 40: Incontinence and ED rates
<1% incontinence <1% ED Aggregated data from 18 publications. References and analysis methodology in appendix. 40
Slide 41: Transfusion rate
<1% incontinence transfusion rate <1% ED Aggregated data from 18 publications. References and analysis methodology in appendix.;Bitar M, et al. Aquablation for benign prostatic hyperplasia: real-world prostate size relevance and bleeding events across 6 years. BJU Int. 2026;137(3):480–484. doi:10.11
Slide 42: Patients Want One Procedure Only
Patients Want One Procedure Only 100% Simple Prostatectomy Aquablation HoLEP Re-operation-free rate (%) 95% REFERENCE TURP STANDARD 90% Rezūm PVP UroLift 85% 80% PAE 75% 0 1 2 3 4 5 6 7 8 9 10 Time after index procedure (years) Rubin B, et al. National review of re-operation rates for modern benign
Slide 43: Aquablation is a Complete Solution for BPH patients
PATIENTS WANT: 1 Complete Symptom Relief PATIENTS WANT: 2 Preserved Sexual and Urinary Function PATIENTS WANT: 3 One Procedure Only Aquablation is a COMPLETE Solution for BPH patients Market research data on file 43
Slide 44: Improving Penetration of Aquablation Within the Surgical Segment
Improving Penetration of Aquablation Within the Surgical Segment ~40 MILLION U.S. men living with BPH 1 Misalignment: In patient priorities and physician assumptions 8M treated or previously treated with medication 2 Surgeon Comfort With 6.7M actively on medication 1.1M discontinued drug therapy Leg
Slide 45: A Complete BPH Solution Through the Lens of What Matters Most to Patients
A Complete BPH Solution Through the Lens of What Matters Most to Patients 45
Slide 46: Operationalizing Our Clinical Differentiation
Operationalizing Our Clinical Differentiation Standardize and strengthen the message Operationalize that message: • Selling tools • Packaged research insights highlighting what BPH patients prioritize • Peer-to-peer education programs 46
Slide 47: Improving Penetration of Aquablation Within the Surgical Segment
Improving Penetration of Aquablation Within the Surgical Segment ~40 MILLION U.S. men living with BPH 1 Misalignment: In patient priorities and physician assumptions 1-2% unaided 8M treated or previously awareness for treated with medication BPH Comfort patients 2 Surgeon With 6.7M actively on medic
Slide 48: We Start With Patients Considering Alternative Surgical Options
We Start With Patients Considering Alternative Surgical Options OBJECTIVE: Share capture within existing surgical market ~40 MILLION APPROACH: U.S. men living with BPH • In-practice education tools (treatment comparison 8M treated or previously treated with medication guides, short videos for consul
Slide 49: Then Expand to Dissatisfied Medically Managed Patients
Then Expand to Dissatisfied Medically Managed Patients Alpha Blockers Tamsulosin: Short-term side effects include: Long-term side effects include: • Dizziness; Fatigue; Ejaculatory • Sexual side effects continue ~40 MILLION changes U.S. men living with BPH 8M treated or previously treated with medic
Slide 50: Then Expand to Dissatisfied Medically Managed Patients
Then Expand to Dissatisfied Medically Managed Patients OBJECTIVE: Educate patients already frustrated with medication and under care of a urologist ~40 MILLION U.S. men living with BPH APPROACH: 8M treated or previously treated with medication • Digital engagement • Geo-targeted digital actively on
Slide 51: Then Expand to Dissatisfied Medically Managed Patients
Then Expand to Dissatisfied Medically Managed Patients ~40 MILLION ~20% Request specific BPH procedures by name U.S. men living with BPH Of BPH Patients 8M treated or previously treated with medication actively on discontinued 6.7M medication 1.1M drug therapy ~400K annual BPH surgical procedures ~1
Slide 52: Long-Term, We Can Broaden Our Educational Efforts
Long-Term, We Can Broaden Our Educational Efforts OBJECTIVE: Build broader awareness only after conversion pathways are validated ~40 MILLION U.S. men living with BPH APPROACH: • Broader therapy development campaigns 8M treated or previously treated with medication actively on discontinued • Patient
Slide 53: Prostate Cancer Opportunity
Multiple Initiatives to Drive Differentiated Growth Across the Horizon Drive Procedure Educate Patients Expand Growth Through That Waiting Applications Improved Execution Isn't Winning ~40 MILLION ~40 MILLION U.S. men living with BPH U.S. men living with BPH 8M treated or previously treated with med
Slide 54: Prostate Cancer: Our Next Frontier
Prostate Cancer: Our Next Frontier Barry Templin Chief Technology Officer © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 54
Slide 55: Prostate Cancer Is A Multifocal Disease Requiring A Whole Gland Treatment
Prostate Cancer Is A Multifocal Disease Requiring A Whole Gland Treatment Prostate cancer is not a focal disease, and focal treatment is limited >40% of patients with GG2 cancer on one side of the prostate had unidentified GG2 cancer on the other side at final pathology1 Visible on MRI Not visible o
Slide 56: Methodical Approach in Evidence Development
Methodical Approach in Evidence Development FEASABILITY FOUNDATIONAL PIVOTAL Endeavor Retrospective PRCT001.A PRCT002 PRCT001.B WATER IV Health Series Study Prospective, Retrospective, Prospective, Retrospective, Prospective, Prospective Feasibility Foundational Foundational Foundational Foundationa
Slide 57: A Typical BPH Surgical Technique: Planning
A Typical BPH Surgical Technique: Planning Aquablation BPH 57
Slide 58: BPH Resection With Aquablation Results in a Large Unobstructed Channel
BPH Resection With Aquablation Results in a Large Unobstructed Channel Sagittal view BLADDER 58
Slide 59: BPH Resection With Aquablation Results in a Large Unobstructed Channel
BPH Resection With Aquablation Results in a Large Unobstructed Channel Transverse view 59
Slide 60: Planning for a Prostate Cancer Case with Aquablation
Planning for a Prostate Cancer Case with Aquablation MRI Details to Help Inform Surgical Approach Aquablation PCa 60
Slide 61: Aquablation for Prostate Cancer Achieves Whole Gland Resection While Sparing the Capsule
Aquablation for Prostate Cancer Achieves Whole Gland Resection While Sparing the Capsule 61
Slide 62: Aquablation's Versatility Can Deliver an Appropriate Procedure for both BPH and PCa Patients
Aquablation's Versatility Can Deliver an Appropriate Procedure for both BPH and PCa Patients 62
Slide 63: Post Aquablation Prostate Cancer Resection: 6M MRI
Post Aquablation Prostate Cancer Resection: 6M MRI MRI Confirmation of Tissue Removal Axial T2-weighted High–b Value Diffusion-Weighted 63
Slide 64: We Are Taking a Methodical Approach in Evidence Development
We Are Taking a Methodical Approach in Evidence Development FEASABILITY FOUNDATIONAL PIVOTAL Endeavor Retrospective PRCT001.A PRCT002 PRCT001.B WATER IV Health Series Study Prospective, Retrospective, Prospective, Retrospective, Prospective, Prospective Feasibility Foundational Foundational Foundati
Slide 65: We Are Taking a Methodical Approach in Evidence Development
We Are Taking a Methodical Approach in Evidence Development FEASABILITY FOUNDATIONAL PIVOTAL PRCT001.A Endeavor Retrospective PRCT001.A PRCT002 PRCT001.B WATER IV Prospective, Health Series Study Feasibility Prospective, Retrospective, Prospective, Retrospective, Prospective, Prospective Feasibility
Slide 66: Enrollment for PRCT001 Now Complete
We Are Taking a Methodical Approach in Evidence Development FEASABILITY FOUNDATIONAL PIVOTAL PRCT001.A PRCT001.B Endeavor Retrospective PRCT001.A PRCT002 PRCT001.B WATER IV Prospective, Health Series Study Prospective, Feasibility Foundational Prospective, Feasibility Enrollment for Retrospective, F
Slide 67: We Are Taking a Methodical Approach in Evidence Development
We Are Taking a Methodical Approach in Evidence Development FEASABILITY FOUNDATIONAL PIVOTAL Endeavor PRCT001.A PRCT001.B Health Series Endeavor Retrospective PRCT001.A PRCT002 PRCT001.B WATER IV Prospective, Health Series Study Prospective, Retrospective, Feasibility Foundational Foundational Prosp
Slide 68: ENDEAVOR Health Series: Aquablation Significantly Slowed the Progression of Cancer
ENDEAVOR Health Series: Aquablation Significantly Slowed the Progression of Cancer 44% Fewer upgrades By removing a moderate amount of prostate at 5 years compared tissue, Aquablation delayed the natural to Active surveillance progression of cancer in this study 68
Slide 69: The PRCT001 Study: Demographics Reflected the Typical Profile of PCa
The PRCT001 Study: Demographics Reflected the Typical Profile of PCa Where Majority of Patients Had Cancer in the Peripheral Zone Patient Demographics Anatomy & Procedure Details Age (years old) 66.4 ±6.7 Prostate Vol. Avg 65.3 ± 31.5 Grade-Group Cancer Location GG1 36% (44/124) Transitional Zone 32
Slide 70: PRCT001 Study: Aquablation Patients Had Stable Erectile Function Through 12 Months
PRCT001 Study: Aquablation Patients Had Stable Erectile Function Through 12 Months Radical Prostatectomy Radical Prostatectomy PROTECT STUDY1 AFU STUDY2 Aquablation3 Avg age = 62 Avg age = 65 Avg age = 66 25 19.0 20 17.5 SHIM Score 16.0 16.7 16.2 15 10 Moderate ED 5.5 6.0 5 4.1 Severe ED 0 Baseline
Slide 71: Aquablation Patients Had Low and Sustained Rates of Urinary Incontinence
The PRCT001 Study: Aquablation Patients Had Low and Sustained Rates of Urinary Incontinence Out to 12 Months Radical Prostatectomy Radical Prostatectomy PROTECT STUDY1 TrueNTH STUDY2 Aquablation3 Avg age = 62 Avg age = 64 Avg age = 66 50 46 40 35 % Pad Use 30 26 20 10 4 3 2 0 0 0 Baseline 6 months 1
Slide 72: Aquablation Patients Had An Additional Benefit of BPH Symptom Reduction
The PRCT001 Study: Aquablation Patients Had An Additional Benefit of BPH Symptom Reduction IPSS Total Score 35 30 Severe (20-35) 25 20 15 17.4 Moderate (8-19) 10 Achievement of 7.7 low IPSS score 5 6.6 5.7 Mild at follow-up (0-7) 0 Baseline 3 month 6 month 12 month 72
Slide 73: Freedom from Additional (Salvage) Treatment vs Radical Prostatectomy
The PRCT001 Study: Freedom from Additional (Salvage) Treatment in Aquablation vs Published Radical Prostatectomy Data Radical Prostatectomy Radical Prostatectomy UCSF1 AFU STUDY2 Aquablation3 98 100 100 100 97 94 96 94 93 93 93 Freedom from Salvage (%) 80 60 40 20 0 3 mo. 6 mo. 9 mo. 12 mo. 3 mo. 6
Slide 74: WATER IV PCa: Aquablation vs. Prostatectomy RCT
WATER IV PCa: Aquablation vs. Prostatectomy RCT Trial design 6-Month 12-Month Ten Year Follow-up Endpoint Key Secondary with Annual Comparative Analyses FDA Analysis Endpoint Aquablation N = 210 Follow-up continues regardless of additional treatments Year 10 Long term follow-up will capture the Co-P
Slide 75: WATER IV Clinical Trial
WATER IV CLINICAL TRIAL One year of enrollment progress Goal: 280 randomized patients 31 global centers recruiting as we exited 2025 Averaging <60 days from consent to treatment On pace to complete all procedures by mid-2026 significantly faster than anticipated 75
Slide 76: Our Technology Enables Expanded Applications Beyond BPH
Our Technology Enables Expanded Applications Beyond BPH Future AI algorithm improvement Expanded patient applications 76
Slide 77: We Believe Aquablation Will Play an Important Role in Treatment of Prostate Cancer
We Believe Aquablation Will Play an Important Role in Treatment of Prostate Cancer 1 2 3 Prostate Cancer is a multi-focal Aquablation therapy can treat the Growing body of clinical evidence disease that requires a whole whole gland including the supports Aquablation can gland treatment peripheral zo
Slide 78: Financial Update
Financial Update Kevin Waters Chief Financial Officer © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 78
Slide 79: Strong track record of driving growth, expanding margins and scaling efficiently
Strong track record of driving growth, expanding margins and scaling efficiently Total Revenue Gross Margin EBITDA Loss* ($M) (%) ($M) $86.5 $309 61.1% 63.7% 52.2% $68.0 49.4% $60.1 $225 $50.2 $136 $75 2022 2023 2024 2025 2022 2023 2024 2025 2022 2023 2024 2025 Revenue Margin Expansion Improved +60%
Slide 80: Aquablation remains significantly underpenetrated in the U.S.
Aquablation remains significantly underpenetrated in the U.S. U.S. Procedures Ending Install Base (000) 718 43.3 505 27.8 315 16.5 167 7.4 2022 2023 2024 2025 2022 2023 2024 2025 Procedure Install Base +80% CAGR +63% CAGR ~10% market penetration1,2 ~25% market penetration1,2 Market penetration estim
Slide 81: Financial Outlook
Financial Outlook © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 81
Slide 82: 2026 – 2027: Key Financial Metrics
2026 – 2027: Key Financial Metrics • 2026 revenue guidance1 of $390 to $410 million, representing growth of 27% to 33% Strong Revenue • 25% to 30% annual revenue growth in 20271 driven by increased Growth procedure growth from new and existing accounts, and Hydros replacement cycle as legacy AquaBea
Slide 83: Scalable Revenue Growth Drivers
Scalable Revenue Growth Drivers Strong Revenue Commercial execution to drive strong Growth revenue growth • Incentivize organic, same facility procedure growth • Activate New Account Launch Teams Expanding gross • Handpiece Pricing Discipline margins • Initiate Replacement Cycle • Explore operating
Slide 84: 2026 Revenue Guidance
2026 Revenue Guidance* $95M to $100M $221M to $235M $390M to $410M System Revenue Handpiece + Other Consumable Revenue Total Revenue $340M to $359M ~$24M $3,500 U.S. Revenue Service Revenue Handpiece Price $50M to $51M Int’l Revenue 60,000 to 64,000 HPs sold to align with Procedures procedure volume
Slide 85: 2026 Guidance Assumes 1:1 HP to Procedure ratio
2026 Guidance* Assumes 1:1 HP to Procedure ratio U.S. Procedures U.S. Handpieces % Handpieces to (000) (000) Procedures 46.6 43.3 115% 32.3 108% 27.8 16.5 18.6 100% 7.4 8.4 2.9 3.3 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021-2024 2025 2026 Handpiece ordering should more closely track proc
Slide 86: 2026 Procedure Contribution Breakdown to Achieve Low End of Guidance Range
2026 Procedure Contribution Breakdown to Achieve Low End of Guidance Range* 2026 Ending Install Base Procedure Contribution by Cohort by Cohort 2025 Cohort will have full year contribution in ~60,000 calendar 2026 208-213 ~8,000 Systems sold With launches occurring Guidance In 2026 ~43,000 throughou
Slide 87: 2026 Revenue Build by Segment
2026 Revenue Build by Segment* Annual Revenue ($M) Factors To Achieve Low-End Range $410 High-end Modest utilization growth in legacy install base $390 Low-end Normal procedure contribution from new account launches Flat New System Revenue $308 $308 2025 Base Handpiece Pricing Benefit Inte
Slide 88: HP pricing will be meaningful revenue tailwind in 2026
HP pricing will be meaningful revenue tailwind in 2026* HP Pricing Trends ($000) +9% $3.50 $3.18 $3.22 • Improved pricing $3.12 discipline • Increased HP list price on January 1, 2026 • Future gross margin tailwind 2023 2024 2025 2026 *2026 financial guidance issued on February 25, 2026 88
Slide 89: Global Revenue Profile
Global Revenue Profile* Global Revenue ($ mil) +25% to 30% $390 - $410 2027 Revenue Drivers +27% to 33% • Growing U.S. Install Base $308 +37% • Increased Replacement Revenue $224.47 • Stable handpiece & system pricing +65% • Continued penetration of UK + Japan market 2024 2025 2026 2027 *2026 + 2027
Slide 90: Long Term Profitability and EBITDA Expansion
Long Term Profitability and EBITDA Expansion 90
Slide 91: Clear Path to Profitability
Clear Path to Profitability Strong Revenue Growth Operational Efficiencies Driven by Expanding gross • HP revenue mix will be meaningful tailwind margins to corporate gross margin expansion • Disciplined HP pricing • Targeting R&D as percent of sales ratio of Improved operating mid-teens long-term l
Slide 92: How to Achieve 68% to 70% gross margin by 2027
How to Achieve 68% to 70% gross margin by 2027*... • Favorable Unit Margin Annual Gross Margin Targets Handpiece • HP revenue will be tailwind to multi-year gross margin expansion as percent of global revenue increases 68-70% 65% • Declining mix of system revenue will reduce pressure 64% Capital on
Slide 93: R&D spend will remain robust, but will be source of future operating leverage
R&D spend will remain robust, but will be meaningful source of future operating leverage* Invest in core Annual R&D Spend R&D as % of Sales strategic areas to accelerate innovation & support growth 36% GROWTH • Clinical evidence • New product 28% development LEVERAGE $71.3 23% Revenue growth $62.3 w
Slide 94: Once positive, adjusted EBITDA is expected to achieve sustained positive momentum
Once positive, adjusted EBITDA1,2 is expected to achieve sustained positive momentum Adjusted EBITDA SG&A Leverage Drivers ($-mil) • Improved sales force +$25 to +$30 productivity • Initiate hybrid clinical support model 2023 2024 2025 2026 2027 -$30 to -$17 • SG&A is expected to drive leverage desp
Slide 95: Balance Sheet and Metrics
Balance Sheet and Metrics 95
Slide 96: Strong balance sheet supports scalable growth
Strong balance sheet supports scalable growth • Continue to drive working capital improvements Operating • Meaningful opportunity to reduce Days Inventory on Hand and Days Cash Flow Sales Outstanding • Do not expect cash balance to drop below $175 million* • Procept requires little CAPEX investment
Slide 97: Moderated Q&A
Moderated Q&A 97
Slide 98: Thank You
THANK YOU
Slide 99: Appendix - Non-GAAP Reconciliations
Appendix - Non-GAAP Reconciliations 99
Slide 100: Risk and Safety Information
Risk and Safety Information All surgical treatments have inherent and associated side effects, some of which may lead to serious outcomes and may require intervention. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristi
Slide 101: Clinical Data Summary Methodology
Clinical Data Summary Methodology Studies with distinct patient cohorts evaluating Aquablation therapy were included, abstracts and unpublished data were excluded; Studies with fewer than 30 patients were excluded; Data was pulled from 18 Aquablation therapy publications up to January 2025; Listed b
Slide 102: Clinical Methodology
Clinical Methodology (Slide 44 & 45) 102